# Victor E Velculescu

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 189 papers | 78,096 citations | 103 h-index | 232 g-index |
| 232 ext. papers | 88,023 ext. citations | 17.8 avg, IF | 7.4 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 189 | WAF1, a potential mediator of p53 tumor suppression. *Cell*, **1993**, 75, 817-25 | 56.2 | 7436 |
| 188 | Cancer genome landscapes. *Science*, **2013**, 339, 1546-58 | 33.3 | 5058 |
| 187 | An integrated genomic analysis of human glioblastoma multiforme. *Science*, **2008**, 321, 1807-12 | 33.3 | 4419 |
| 186 | IDH1 and IDH2 mutations in gliomas. *New England Journal of Medicine*, **2009**, 360, 765-73 | 59.2 | 4220 |
| 185 | Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science*, **2008**, 321, 1801-6 | 33.3 | 3223 |
| 184 | The consensus coding sequences of human breast and colorectal cancers. *Science*, **2006**, 314, 268-74 | 33.3 | 2832 |
| 183 | Detection of circulating tumor DNA in early- and late-stage human malignancies. *Science Translational Medicine*, **2014**, 6, 224ra24 | 17.5 | 2741 |
| 182 | The genomic landscapes of human breast and colorectal cancers. *Science*, **2007**, 318, 1108-13 | 33.3 | 2717 |
| 181 | High frequency of mutations of the PIK3CA gene in human cancers. *Science*, **2004**, 304, 554 | 33.3 | 2657 |
| 180 | Distant metastasis occurs late during the genetic evolution of pancreatic cancer. *Nature*, **2010**, 467, 1114-7 | 50.4 | 1834 |
| 179 | International network of cancer genome projects. *Nature*, **2010**, 464, 993-8 | 50.4 | 1613 |
| 178 | Genes expressed in human tumor endothelium. *Science*, **2000**, 289, 1197-202 | 33.3 | 1583 |
| 177 | Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. *Science*, **2011**, 333, 1154-7 | 33.3 | 1331 |
| 176 | DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. *Science*, **2011**, 331, 1199-203 | 33.3 | 1252 |
| 175 | Gene expression profiles in normal and cancer cells. *Science*, **1997**, 276, 1268-72 | 33.3 | 1217 |
| 174 | TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 6021-6 | 11.5 | 968 |
| 173 | Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. *Nature*, **2002**, 418, 934 | 50.4 | 962 |

| | | | |
|---|---|---|---|
| 172 | Characterization of the yeast transcriptome. *Cell*, **1997**, 88, 243-51 | 56.2 | 924 |
| 171 | Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. *Science*, **2010**, 330, 228-31 | 33.3 | 915 |
| 170 | Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. *New England Journal of Medicine*, **2018**, 378, 1976-1986 | 59.2 | 865 |
| 169 | The colorectal microRNAome. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 3687-92 | 11.5 | 797 |
| 168 | Mutant PIK3CA promotes cell growth and invasion of human cancer cells. *Cancer Cell*, **2005**, 7, 561-73 | 24.3 | 726 |
| 167 | Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. *Science*, **2009**, 325, 1555-9 | 33.3 | 680 |
| 166 | Analysis of human transcriptomes. *Nature Genetics*, **1999**, 23, 387-8 | 36.3 | 639 |
| 165 | AACR Project GENIE: Powering Precision Medicine through an International Consortium. *Cancer Discovery*, **2017**, 7, 818-831 | 24.4 | 629 |
| 164 | Comparative lesion sequencing provides insights into tumor evolution. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 4283-8 | 11.5 | 616 |
| 163 | Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science*, **2009**, 324, 217 | 33.3 | 608 |
| 162 | The genetic landscape of the childhood cancer medulloblastoma. *Science*, **2011**, 331, 435-9 | 33.3 | 576 |
| 161 | Allelic variation in human gene expression. *Science*, **2002**, 297, 1143 | 33.3 | 567 |
| 160 | A phosphatase associated with metastasis of colorectal cancer. *Science*, **2001**, 294, 1343-6 | 33.3 | 539 |
| 159 | Direct detection of early-stage cancers using circulating tumor DNA. *Science Translational Medicine*, **2017**, 9, | 17.5 | 537 |
| 158 | The PIK3CA gene is mutated with high frequency in human breast cancers. *Cancer Biology and Therapy*, **2004**, 3, 772-5 | 4.6 | 536 |
| 157 | Using the transcriptome to annotate the genome. *Nature Biotechnology*, **2002**, 20, 508-12 | 44.5 | 528 |
| 156 | Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. *Nature Genetics*, **2001**, 28, 184-7 | 36.3 | 524 |
| 155 | Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. *Cancer Discovery*, **2017**, 7, 264-276 | 24.4 | 491 |

| | | | |
|---|---|---|---|
| 154 | Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. *Cancer Discovery*, **2013**, 3, 658-73 | 24.4 | 489 |
| 153 | Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. *Cancer Discovery* , **2014**, 4, 650-61 | 24.4 | 473 |
| 152 | Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. *Nature Genetics*, **2013**, 45, 1470-1473 | 36.3 | 464 |
| 151 | Inactivation of hCDC4 can cause chromosomal instability. *Nature*, **2004**, 428, 77-81 | 50.4 | 464 |
| 150 | Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. *Science Translational Medicine*, **2012**, 4, 162ra154 | 17.5 | 463 |
| 149 | Colorectal cancer: mutations in a signalling pathway. *Nature*, **2005**, 436, 792 | 50.4 | 452 |
| 148 | The antisense transcriptomes of human cells. *Science*, **2008**, 322, 1855-7 | 33.3 | 436 |
| 147 | Mutational analysis of the tyrosine phosphatome in colorectal cancers. *Science*, **2004**, 304, 1164-6 | 33.3 | 431 |
| 146 | The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. *Science*, **2007**, 318, 1744-8 | 33.3 | 430 |
| 145 | Distinct epigenetic changes in the stromal cells of breast cancers. *Nature Genetics*, **2005**, 37, 899-905 | 36.3 | 423 |
| 144 | Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. *Nature*, **2010**, 464, 610-4 | 50.4 | 415 |
| 143 | Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. *Cancer Research*, **2004**, 64, 8816-20 | 10.1 | 404 |
| 142 | Development of personalized tumor biomarkers using massively parallel sequencing. *Science Translational Medicine*, **2010**, 2, 20ra14 | 17.5 | 401 |
| 141 | Mutations in CIC and FUBP1 contribute to human oligodendroglioma. *Science*, **2011**, 333, 1453-5 | 33.3 | 399 |
| 140 | Mutational analysis of the tyrosine kinome in colorectal cancers. *Science*, **2003**, 300, 949 | 33.3 | 392 |
| 139 | Oncogenic mutations of PIK3CA in human cancers. *Cell Cycle*, **2004**, 3, 1221-4 | 4.7 | 384 |
| 138 | ATM mutations in patients with hereditary pancreatic cancer. *Cancer Discovery*, **2012**, 2, 41-6 | 24.4 | 365 |
| 137 | Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. *Cancer Research*, **2009**, 69, 6660-7 | 10.1 | 344 |

| | | | |
|---|---|---|---|
| 136 | Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. *Nature Genetics*, **2011**, 43, 828-9 | 36.3 | 342 |
| 135 | Genome-wide cell-free DNA fragmentation in patients with cancer. *Nature*, **2019**, 570, 385-389 | 50.4 | 339 |
| 134 | Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. *American Journal of Pathology*, **2009**, 174, 1597-601 | 5.8 | 339 |
| 133 | Epitope landscape in breast and colorectal cancer. *Cancer Research*, **2008**, 68, 889-92 | 10.1 | 328 |
| 132 | High grade serous ovarian carcinomas originate in the fallopian tube. *Nature Communications*, **2017**, 8, 1093 | 17.4 | 325 |
| 131 | Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 3443-8 | 11.5 | 314 |
| 130 | The genomic landscape of response to EGFR blockade in colorectal cancer. *Nature*, **2015**, 526, 263-7 | 50.4 | 310 |
| 129 | Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. *Cancer Discovery*, **2012**, 2, 899-905 | 24.4 | 301 |
| 128 | Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. *Nature Genetics*, **2013**, 45, 12-7 | 36.3 | 300 |
| 127 | Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. *Cancer Research*, **2004**, 64, 5048-50 | 10.1 | 290 |
| 126 | Personalized genomic analyses for cancer mutation discovery and interpretation. *Science Translational Medicine*, **2015**, 7, 283ra53 | 17.5 | 281 |
| 125 | Genetic progression and the waiting time to cancer. *PLoS Computational Biology*, **2007**, 3, e225 | 5 | 280 |
| 124 | Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. *Nature Communications*, **2015**, 6, 7686 | 17.4 | 279 |
| 123 | SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. *Clinical Cancer Research*, **2009**, 15, 4674-9 | 12.9 | 275 |
| 122 | Sensitive digital quantification of DNA methylation in clinical samples. *Nature Biotechnology*, **2009**, 27, 858-63 | 44.5 | 273 |
| 121 | Somatic mutations of EGFR in colorectal cancers and glioblastomas. *New England Journal of Medicine*, **2004**, 351, 2883 | 59.2 | 255 |
| 120 | Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. *Human Mutation*, **2012**, 33, 100-3 | 4.7 | 230 |
| 119 | Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 16224-9 | 11.5 | 230 |

| | | | |
|---|---|---|---|
| 118 | Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. *Cell*, **2017**, 171, 1284-1300.e21 | 56.2 | 215 |
| 117 | Implications of micro-RNA profiling for cancer diagnosis. *Oncogene*, **2006**, 25, 6220-7 | 9.2 | 214 |
| 116 | Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. *Clinical Cancer Research*, **2011**, 17, 1591-602 | 12.9 | 198 |
| 115 | Digital karyotyping. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 16156-61 | 11.5 | 191 |
| 114 | Changes in gene expression associated with developmental arrest and longevity in Caenorhabditis elegans. *Genome Research*, **2001**, 11, 1346-52 | 9.7 | 186 |
| 113 | Analysing uncharted transcriptomes with SAGE. *Trends in Genetics*, **2000**, 16, 423-5 | 8.5 | 186 |
| 112 | Recurrent KRAS codon 146 mutations in human colorectal cancer. *Cancer Biology and Therapy*, **2006** , 5, 928-32 | 4.6 | 171 |
| 111 | Three classes of genes mutated in colorectal cancers with chromosomal instability. *Cancer Research* , **2004**, 64, 2998-3001 | 10.1 | 165 |
| 110 | Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. *Clinical Cancer Research*, **2012**, 18, 6339-47 | 12.9 | 163 |
| 109 | Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 3089-94 | 11.5 | 163 |
| 108 | Prevalence of somatic alterations in the colorectal cancer cell genome. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 3076-80 | 11.5 | 163 |
| 107 | Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 4060-4 | 11.5 | 158 |
| 106 | Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E364-9 | 5.6 | 157 |
| 105 | Low-grade serous carcinomas of the ovary contain very few point mutations. *Journal of Pathology*, **2012**, 226, 413-20 | 9.4 | 154 |
| 104 | Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. *Cancer Biology and Therapy*, **2006**, 5, 779-85 | 4.6 | 149 |
| 103 | Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade **2014**, 2, 42 | | 148 |
| 102 | The predictive capacity of personal genome sequencing. *Science Translational Medicine*, **2012**, 4, 133ra58 | 17.5 | 147 |
| 101 | PRL-3 expression in metastatic cancers. *Clinical Cancer Research*, **2003**, 9, 5607-15 | 12.9 | 133 |

| | | | |
|---|---|---|---|
| 100 | Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. *Nature Communications*, **2016**, 7, 11971 | 17.4 | 125 |
| 99 | Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. *Cancer Research*, **2007**, 67, 9364-70 | 10.1 | 124 |
| 98 | Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. *Nature Communications*, **2014**, 5, 5006 | 17.4 | 120 |
| 97 | Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. *Clinical Cancer Research*, **2014**, 20, 2476-84 | 12.9 | 118 |
| 96 | Mutant metabolic enzymes are at the origin of gliomas. *Cancer Research*, **2009**, 69, 9157-9 | 10.1 | 117 |
| 95 | Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. *Cancer Research*, **2019**, 79, 1214-1225 | 10.1 | 117 |
| 94 | Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations. *Cancer Cell*, **2017**, 32, 360-376.e6 | 24.3 | 116 |
| 93 | Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. *PLoS Medicine*, **2008**, 5, e114 | 11.6 | 113 |
| 92 | Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 12921-5 | 11.5 | 112 |
| 91 | Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. *Cancer Research*, **2005**, 65, 919-24 | 10.1 | 110 |
| 90 | The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA. *Clinical Cancer Research*, **2017**, 23, 2471-2477 | 12.9 | 109 |
| 89 | A multidimensional analysis of genes mutated in breast and colorectal cancers. *Genome Research*, **2007**, 17, 1304-18 | 9.7 | 106 |
| 88 | Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer. *Epigenetics*, **2014**, 9, 1031-46 | 5.7 | 105 |
| 87 | The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT. *Nature Biotechnology*, **2006**, 24, 1573-80 | 44.5 | 105 |
| 86 | Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. *Clinical Cancer Research*, **2012**, 18, 4257-65 | 12.9 | 101 |
| 85 | Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 2598-603 | 11.5 | 97 |
| 84 | Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. *Oncotarget*, **2018**, 9, 28561-28571 | 3.3 | 92 |
| 83 | NORF5/HUG1 is a component of the MEC1-mediated checkpoint response to DNA damage and replication arrest in Saccharomyces cerevisiae. *Molecular and Cellular Biology*, **1999**, 19, 7041-9 | 4.8 | 89 |

| | | | |
|---|---|---|---|
| 82 | Genetic mutations associated with cigarette smoking in pancreatic cancer. *Cancer Research*, **2009**, 69, 3681-8 | 10.1 | 88 |
| 81 | Precancer Atlas to Drive Precision Prevention Trials. *Cancer Research*, **2017**, 77, 1510-1541 | 10.1 | 81 |
| 80 | Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. *Molecular Cancer Therapeutics*, **2013**, 12, 1002-15 | 6.1 | 80 |
| 79 | Design and analysis issues in genome-wide somatic mutation studies of cancer. *Genomics*, **2009**, 93, 17-21 | 4.3 | 75 |
| 78 | Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. *Cancer Cell*, **2020**, 38, 500-515.e3 | 24.3 | 75 |
| 77 | Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. *Human Mutation*, **2006**, 27, 1060-1 | 4.7 | 73 |
| 76 | Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. *American Journal of Pathology*, **2011**, 178, 1442-7 | 5.8 | 72 |
| 75 | Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. *Clinical Cancer Research*, **2017**, 23, 1263-1273 | 12.9 | 67 |
| 74 | Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. *Nature Cancer*, **2020**, 1, 99-111 | 15.4 | 67 |
| 73 | Notch1 mutations are drivers of oral tumorigenesis. *Cancer Prevention Research*, **2015**, 8, 277-286 | 3.2 | 64 |
| 72 | White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. *Nature Communications*, **2020**, 11, 525 | 17.4 | 64 |
| 71 | Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. *Nature Communications*, **2020**, 11, 3726 | 17.4 | 61 |
| 70 | The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. *Cancer Immunology Research*, **2018**, 6, 888-899 | 12.5 | 60 |
| 69 | Cancer DNA in the Circulation: The Liquid Biopsy. *JAMA - Journal of the American Medical Association*, **2017**, 318, 1272-1274 | 27.4 | 55 |
| 68 | Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. *Clinical Cancer Research*, **2019**, 25, 4973-4984 | 12.9 | 55 |
| 67 | Patient-oriented gene set analysis for cancer mutation data. *Genome Biology*, **2010**, 11, R112 | 18.3 | 54 |
| 66 | Beyond genomics: critical evaluation of cell line utility for ovarian cancer research. *Gynecologic Oncology*, **2015**, 139, 97-103 | 4.9 | 52 |
| 65 | Defining the blueprint of the cancer genome. *Carcinogenesis*, **2008**, 29, 1087-91 | 4.6 | 51 |

| | | | |
|---|---|---|---|
| 64 | Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. *Cancer Research*, **2019**, 79, 1204-1213 | 10.1 | 50 |
| 63 | Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. *Cell Reports* , **2018**, 25, 2617-2633 | 10.6 | 49 |
| 62 | Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade. *Clinical Cancer Research*, **2019**, 25, 7024-7034 | 12.9 | 48 |
| 61 | Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2020**, 26, 1327-1337 | 12.9 | 46 |
| 60 | Sodium ion channel mutations in glioblastoma patients correlate with shorter survival. *Molecular Cancer*, **2011**, 10, 17 | 42.1 | 44 |
| 59 | A machine learning approach for somatic mutation discovery. *Science Translational Medicine*, **2018**, 10, | 17.5 | 44 |
| 58 | Homozygous deletion of MKK4 in ovarian serous carcinoma. *Cancer Biology and Therapy*, **2006**, 5, 630-4 | 4.6 | 43 |
| 57 | Mutational analysis of gene families in human cancer. *Current Opinion in Genetics and Development*, **2005**, 15, 5-12 | 4.9 | 40 |
| 56 | Essay: Amersham Pharmacia Biotech & Science prize. Tantalizing transcriptomes--SAGE and its use in global gene expression analysis. *Science*, **1999**, 286, 1491-2 | 33.3 | 40 |
| 55 | Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer **2020**, 8, | | 40 |
| 54 | Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. *Nature*, **2021**, 596, 126-132 | 50.4 | 40 |
| 53 | High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets. *Cancer Immunology Research*, **2020**, 8, 396-408 | 12.5 | 38 |
| 52 | Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. *Molecular Cancer Therapeutics*, **2016**, 15, 1746-56 | 6.1 | 37 |
| 51 | High-throughput gene expression analysis using SAGE. *Drug Discovery Today*, **1998**, 3, 152-159 | 8.8 | 35 |
| 50 | Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. *Oncotarget*, **2013**, 4, 1856-7 | 3.3 | 35 |
| 49 | Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. *Clinical Cancer Research*, **2014**, 20, 2947-58 | 12.9 | 34 |
| 48 | Genome-wide linkage scan for colorectal cancer susceptibility genes supports linkage to chromosome 3q. *BMC Cancer*, **2008**, 8, 87 | 4.8 | 32 |
| 47 | Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 **2019**, 7, 40 | | 28 |

| | | | |
|---|---|---|---|
| 46 | Genomic characterization of malignant progression in neoplastic pancreatic cysts. *Nature Communications*, **2020**, 11, 4085 | 17.4 | 27 |
| 45 | Combined MEK and BCL-2/X Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. *Molecular Cancer Therapeutics*, **2019**, 18, 642-655 | 6.1 | 26 |
| 44 | Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia. *Leukemia*, **2011**, 25, 1908-10 | 10.7 | 26 |
| 43 | Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. *Clinical Cancer Research*, **2019**, 25, 7287-7293 | 13.9 | 25 |
| 42 | Identification of microbial DNA in human cancer. *BMC Medical Genomics*, **2009**, 2, 22 | 3.7 | 22 |
| 41 | Digital karyotyping. *Nature Protocols*, **2007**, 2, 1973-86 | 18.8 | 22 |
| 40 | Detection and characterization of lung cancer using cell-free DNA fragmentomes. *Nature Communications*, **2021**, 12, 5060 | 17.4 | 21 |
| 39 | Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. *British Journal of Cancer*, **2017**, 117, 572-582 | 8.7 | 18 |
| 38 | Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers.. *Journal of Clinical Oncology*, **2017**, 35, 8508-8508 | 2.2 | 18 |
| 37 | Evaluation of machine learning methods to predict peptide binding to MHC Class I proteins | | 18 |
| 36 | Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. *Cell Reports Medicine*, **2020**, 1, 100139 | 18 | 17 |
| 35 | Large-scale identification of novel transcripts in the human genome. *Genome Research*, **2007**, 17, 287-92 | 9.7 | 15 |
| 34 | Abstract NG01: Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer **2017**, | | 15 |
| 33 | Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. *Nature Medicine*, **2021**, 27, 1910-1920 | 50.5 | 14 |
| 32 | Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs). *Journal of Proteome Research*, **2012**, 11, 5556-63 | 5.6 | 13 |
| 31 | Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes. *Molecular Cancer Research*, **2012**, 10, 739-49 | 6.6 | 13 |
| 30 | American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member InstitutionsSPerspectives. *JCO Clinical Cancer Informatics*, **2018**, 2, 1-14 | 5.2 | 13 |
| 29 | Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer. *Molecular Diagnosis and Therapy*, **2017**, 21, 375-384 | 4.5 | 10 |

| | | | |
|---|---|---|---|
| 28 | Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer.. *Journal of Clinical Oncology*, **2019**, 37, 142-142 | 2.2 | 10 |
| 27 | Genome-wide investigation of intragenic DNA methylation identifies ZMIZ1 gene as a prognostic marker in glioblastoma and multiple cancer types. *International Journal of Cancer*, **2019**, 145, 3425-3435 | 7.5 | 9 |
| 26 | Functional synergies yet distinct modulators affected by genetic alterations in common human cancers. *Cancer Research*, **2011**, 71, 3471-81 | 10.1 | 9 |
| 25 | Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer. *Journal of Molecular Diagnostics*, **2020**, 22, 1430-1437 | 5.1 | 6 |
| 24 | Understanding the enemy. *Science Translational Medicine*, **2011**, 3, 98ps37 | 17.5 | 4 |
| 23 | Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk. *Journal of Thoracic Oncology*, **2020**, 15, 1871-1879 | 8.9 | 4 |
| 22 | Abstract 619: Identification of clinically actionable genomic alterations in the tumor and circulation of pancreatic cancer patients **2015**, | | 3 |
| 21 | Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma.. *Journal of Clinical Oncology*, **2015**, 33, e15213-e15213 | 2.2 | 3 |
| 20 | Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition. *JCO Precision Oncology*, **2018**, 2, | 3.6 | 3 |
| 19 | TRAB: testing whether mutation frequencies are above an unknown background. *Statistical Applications in Genetics and Molecular Biology*, **2008**, 7, Article11 | 1.2 | 2 |
| 18 | Abstract CT079: Neoadjuvant PD-1 blockade in resectable lung cancer **2018**, | | 2 |
| 17 | A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases. *JCO Precision Oncology*, **2021**, 5, | 3.6 | 2 |
| 16 | Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer.. *Journal of Clinical Oncology*, **2016**, 34, e20005-e20005 | 2.2 | 1 |
| 15 | Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).. *Journal of Clinical Oncology*, **2018**, 36, 11510-11510 | 2.2 | 1 |
| 14 | Circulating tumor DNA dynamics in resectable gastric cancer.. *Journal of Clinical Oncology*, **2018**, 36, 4069-4069 | 2.2 | 1 |
| 13 | Immune checkpoint inhibition in elderly non-small cell lung cancer patients.. *Journal of Clinical Oncology*, **2018**, 36, 137-137 | 2.2 | 1 |
| 12 | Early shifts in immune cell subsets to predict response to immune checkpoint blockade in non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2019**, 37, 105-105 | 2.2 | 1 |
| 11 | Inherited rare, deleterious variants in ATM increase lung adenocarcinoma risk | | 1 |

| | | | |
|---|---|---|---|
| 10 | Pan-Cancer assessment of tumor mutational burden using a comprehensive genomic profiling assay.. *Journal of Clinical Oncology*, **2018**, 36, 157-157 | 2.2 | 1 |
| 9 | Personalized Genomic Analyses for Cancer Mutation Discovery and Interpretation.. *Journal of Clinical Oncology*, **2015**, 33, 1529-1529 | 2.2 | 1 |
| 8 | Response to Comments on "The Predictive Capacity of Personal Genome Sequencing". *Science Translational Medicine*, **2012**, 4, 135lr3-135lr3 | 17.5 | 0 |
| 7 | Amplification in DNA Copy Numbers as a Mechanism of Acquired Drug Resistance **2006**, 531-540 | | |
| 6 | Induction nivolumab or nivolumab/ipilimumab prior to concurrent chemoradiation plus nivolumab in patients with operable stage II/III esophageal/gastroesophageal junction cancer.. *Journal of Clinical Oncology*, **2018**, 36, TPS4140-TPS4140 | 2.2 | |
| 5 | Genome-wide cell-free DNA fragmentation profiling for early cancer detection.. *Journal of Clinical Oncology*, **2019**, 37, 3018-3018 | 2.2 | |
| 4 | Integrated next-generation sequencing and patient-derived xenografts to personalized cancer treatment.. *Journal of Clinical Oncology*, **2012**, 30, 3068-3068 | 2.2 | |
| 3 | Modeling cell-free DNA fragment size densities for non-invasive detection of cancer.. *Journal of Clinical Oncology*, **2021**, 39, 3058-3058 | 2.2 | |
| 2 | Immunogenomic features of pathologic response to neoadjuvant immune checkpoint blockade in esophageal cancer.. *Journal of Clinical Oncology*, **2021**, 39, 4042-4042 | 2.2 | |
| 1 | Natural Language Processing Approaches for Retrieval of Clinically Relevant Genomic Information in Cancer. *Studies in Health Technology and Informatics*, **2022**, | 0.5 | |